View Item 

Show simple item record

Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases

dc.contributor.authorBrown, Kevin K.
dc.contributor.authorInoue, Yoshikazu
dc.contributor.authorFlaherty, Kevin R.
dc.contributor.authorMartinez, Fernando J.
dc.contributor.authorCottin, Vincent
dc.contributor.authorBonella, Francesco
dc.contributor.authorCerri, Stefania
dc.contributor.authorDanoff, Sonye K.
dc.contributor.authorJouneau, Stephane
dc.contributor.authorGoeldner, Rainer-Georg
dc.contributor.authorSchmidt, Martin
dc.contributor.authorStowasser, Susanne
dc.contributor.authorSchlenker-Herceg, Rozsa
dc.contributor.authorWells, Athol U.
dc.date.accessioned2022-04-08T18:01:29Z
dc.date.available2023-05-08 14:01:28en
dc.date.available2022-04-08T18:01:29Z
dc.date.issued2022-04
dc.identifier.citationBrown, Kevin K.; Inoue, Yoshikazu; Flaherty, Kevin R.; Martinez, Fernando J.; Cottin, Vincent; Bonella, Francesco; Cerri, Stefania; Danoff, Sonye K.; Jouneau, Stephane; Goeldner, Rainer-Georg ; Schmidt, Martin; Stowasser, Susanne; Schlenker-Herceg, Rozsa ; Wells, Athol U. (2022). "Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases." Respirology 27(4): 294-300.
dc.identifier.issn1323-7799
dc.identifier.issn1440-1843
dc.identifier.urihttps://hdl.handle.net/2027.42/171966
dc.description.abstractBackground and objectiveDemographic and clinical variables, measured at baseline or over time, have been associated with mortality in subjects with progressive fibrosing interstitial lung diseases (ILDs). We used data from the INPULSIS trials in subjects with idiopathic pulmonary fibrosis (IPF) and the INBUILD trial in subjects with other progressive fibrosing ILDs to assess relationships between demographic/clinical variables and mortality.MethodsThe relationships between baseline variables and time-varying covariates and time to death over 52 weeks were analysed using pooled data from the INPULSIS trials and, separately, the INBUILD trial using a Cox proportional hazards model.ResultsOver 52 weeks, 68/1061 (6.4%) and 33/663 (5.0%) subjects died in the INPULSIS and INBUILD trials, respectively. In the INPULSIS trials, a relative decline in forced vital capacity (FVC) >10% predicted within 12 months (hazard ratio [HR] 3.77) and age (HR 1.03 per 1-year increase) were associated with increased risk of mortality, while baseline FVC % predicted (HR 0.97 per 1-unit increase) and diffusing capacity of the lungs for carbon monoxide (DLCO) % predicted (HR 0.77 per 1-unit increase) were associated with lower risk. In the INBUILD trial, a relative decline in FVC >10% predicted within 12 months (HR 2.60) and a usual interstitial pneumonia-like fibrotic pattern on HRCT (HR 2.98) were associated with increased risk of mortality, while baseline DLCO % predicted (HR 0.95 per 1-unit increase) was associated with lower risk.ConclusionThese data support similarity in the course of lung injury between IPF and other progressive fibrosing ILDs and the value of FVC decline as a predictor of mortality.We assessed relationships between baseline and time-varying factors and mortality over 52 weeks in 1061 subjects with idiopathic pulmonary fibrosis (IPF) and 663 subjects with other progressive fibrosing interstitial lung diseases (ILDs). Our findings support similarity in the course of IPF and ILD and an association between decline in forced vital capacity and mortality.
dc.publisherJohn Wiley & Sons, Ltd
dc.subject.otherpulmonary function test
dc.subject.otherclinical trial
dc.subject.otherdeath
dc.subject.otherfibrosing interstitial lung disease
dc.subject.otherforced vital capacity
dc.subject.otherpulmonary fibrosis
dc.titlePredictors of mortality in subjects with progressive fibrosing interstitial lung diseases
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171966/1/resp14231.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/171966/2/resp14231_am.pdf
dc.identifier.doi10.1111/resp.14231
dc.identifier.sourceRespirology
dc.identifier.citedreferenceSnyder L, Neely ML, Hellkamp AS, O’Brien E, de Andrade J, Conoscenti CS, et al. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir Res. 2019; 20: 105.
dc.identifier.citedreferenceRaghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018; 198: e44 – 68.
dc.identifier.citedreferenceWells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ, IPF Consensus Working Group. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018; 51 ( 5 ): pii:1800692.
dc.identifier.citedreferenceNasser M, Larrieu S, Si-Mohamed S, Ahmad K, Boussel L, Brevet M, et al. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). Eur Respir J. 2021; 57: 2002718.
dc.identifier.citedreferenceWijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020; 383: 958 – 68.
dc.identifier.citedreferenceRicheldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370: 2071 – 82.
dc.identifier.citedreferenceFlaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019; 381: 1718 – 27.
dc.identifier.citedreferenceWells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, et al. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020; 8: 453 – 60.
dc.identifier.citedreferenceBrown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R, et al. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020; 55: 2000085.
dc.identifier.citedreferenceFlaherty KR, Mumford JA, Murray S, Kazerooni EA, Gross BH, Colby TV, et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003; 168: 543 – 8.
dc.identifier.citedreferenceCollard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003; 168: 538 – 42.
dc.identifier.citedreferenceRicheldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax. 2012; 67: 407 – 11.
dc.identifier.citedreferenceWalsh SL, Sverzellati N, Devaraj A, Wells AU, Hansell DM. Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants. Eur Radiol. 2012; 22: 1672 – 9.
dc.identifier.citedreferenceRyerson CJ, Urbania TH, Richeldi L, Mooney JJ, Lee JS, Jones KD, et al. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013; 42: 750 – 7.
dc.identifier.citedreferenceSolomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, et al. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2016; 47: 588 – 96.
dc.identifier.citedreferenceGoh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, Maher TM, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol. 2017; 69: 1670 – 8.
dc.identifier.citedreferenceGimenez A, Storrer K, Kuranishi L, Soares MR, Ferreira RG, Pereira CAC. Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. Thorax. 2018; 73: 391 – 2.
dc.identifier.citedreferenceAdegunsoye A, Oldham JM, Bellam SK, Montner S, Churpek MM, Noth I, et al. Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases. Ann Am Thorac Soc. 2019; 16: 580 – 8.
dc.identifier.citedreferenceChan C, Ryerson CJ, Dunne JV, Wilcox PG. Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study. BMC Pulm Med. 2019; 19: 192.
dc.identifier.citedreferenceSingh N, Varghese J, England BR, Solomon JJ, Michaud K, Mikuls TR, et al. Impact of the pattern of interstitial lung disease on mortality in rheumatoid arthritis: a systematic literature review and meta-analysis. Semin Arthritis Rheum. 2019; 49: 358 – 65.
dc.identifier.citedreferenceCro S, Morris TP, Kenward MG, Carpenter JR. Reference-based sensitivity analysis via multiple imputation for longitudinal trials with protocol deviation. Stata J. 2016; 16: 443 – 63.
dc.identifier.citedreferencedu Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med. 2011; 184: 1382 – 9.
dc.identifier.citedreferenceVolkmann ER, Tashkin DP, Sim M, Li N, Goldmuntz E, Keyes-Elstein L, et al. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Ann Rheum Dis. 2019; 78: 122 – 30.
dc.identifier.citedreferenceKrauss E, El-Guelai M, Pons-Kuehnemann J, Dartsch RC, Tello S, Korfei M, et al. Clinical and functional characteristics of patients with unclassifiable interstitial lung disease (uILD): long-term follow-up data from European IPF Registry (eurIPFreg). J Clin Med. 2020; 9: 2499.
dc.identifier.citedreferenceDoubková M, Švancara J, Svoboda M, Šterclová M, Bartoš V, Plačková M, et al. EMPIRE Registry, Czech part: impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. Clin Respir J. 2018; 12: 1526 – 35.
dc.identifier.citedreferenceKim HC, Lee JH, Chae EJ, Song JS, Song JW. Long-term clinical course and outcome of interstitial pneumonia with autoimmune features. Respirology. 2020; 25: 636 – 43.
dc.identifier.citedreferenceJo HE, Glaspole I, Grainge C, Goh N, Hopkins PM, Moodley Y, et al. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry. Eur Respir J. 2017; 49: 1601592.
dc.identifier.citedreferenceKelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics – a large multicentre UK study. Rheumatology (Oxford). 2014; 53: 1676 – 82.
dc.identifier.citedreferenceWalsh SL, Sverzellati N, Devaraj A, Keir GJ, Wells AU, Hansell DM. Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax. 2014; 69: 216 – 22.
dc.identifier.citedreferenceSalisbury ML, Gu T, Murray S, Gross BH, Chughtai A, Sayyouh M, et al. Hypersensitivity pneumonitis: radiologic phenotypes are associated with distinct survival time and pulmonary function trajectory. Chest. 2019; 155: 699 – 711.
dc.identifier.citedreferenceJo HE, Glaspole I, Moodley Y, Chapman S, Ellis S, Goh N, et al. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. BMC Pulm Med. 2018; 18: 19.
dc.identifier.citedreferenceBehr J, Prasse A, Wirtz H, Koschel D, Pittrow D, Held M, et al. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry. Eur Respir J. 2020; 56: 1902279.
dc.identifier.citedreferenceTran T, Šterclová M, Mogulkoc N, Lewandowska K, Müller V, Hájková M, et al. The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis. Respir Res. 2020; 21: 11.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
resp14231.pdf
Size:
671.5KB
Format:
PDF
View/Open
Name:
resp14231_am.pdf
Size:
369.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.